Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 31
Back to Home
CJC-1295
GH Increase2-3x
Studies4
Participants85
StatusAvailable

CJC-1295

CJC-1295 with DAC (Drug Affinity Complex)

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) designed to stimulate natural growth hormone production from the pituitary gland. Its unique Drug Affinity Complex (DAC) modification allows it to bind to albumin, extending its half-life to 6-8 days and enabling sustained pulsatile growth hormone release. Unlike direct growth hormone therapy, CJC-1295 works with the body's natural rhythms to optimize anabolic effects while maintaining physiological hormone patterns.

Clinical Benefits

Increases growth hormone levels by 2-10 fold for over 6 days
Elevates IGF-1 levels by 1.5-3 fold for 9-11 days with single dose
Promotes lean muscle mass gain (up to 5% increase in studies)
Reduces visceral fat mass (up to 8% reduction observed)
Enhances bone mineral density (up to 7% improvement)
Improves protein synthesis rates (15% increase in animal studies)

Mechanism of Action

CJC-1295 binds with high affinity to the growth hormone-releasing hormone receptor (GHRHR) on somatotroph cells within the anterior pituitary gland, triggering a cascade of intracellular signaling that includes activation of adenylate cyclase, elevation of cyclic AMP (cAMP) levels, and subsequent activation of protein kinase A (PKA). This leads to pulsatile release of growth hormone in a physiologically relevant pattern, mimicking natural GHRH activity. The peptide's prolonged half-life, facilitated by its conjugation with a drug affinity complex (DAC) via a maleimide-linked lysine, enhances albumin binding in serum, extending its bioavailability to approximately 6-8 days. Downstream, it stimulates insulin-like growth factor 1 (IGF-1) production in the liver and peripheral tissues, promoting anabolic effects on muscle, bone, and fat metabolism without significantly upregulating other hormones like cortisol or prolactin.

Key Action: Growth hormone releasing hormone analog - stimulates natural pulsatile growth hormone release via GHRHR

Proven Results

%
Maximum Weight Loss
Clinical research data
0%
Diabetes Risk Reduction
Clinical research data
85
Total Participants
Research studies
0%
CV Risk Reduction
Clinical data

Medical Disclaimer

CJC-1295 is an investigational research compound not approved by the FDA for human therapeutic use. This information is for educational purposes only and should not be construed as medical advice. Any use should occur only under medical supervision in approved research settings. Long-term effects are not well-studied in humans.